Summary
Pfizer Inc. (PFE) filed an 8-K on October 31, 2023, to report its financial results for the third quarter of 2023. The filing primarily incorporates by reference a press release issued on the same date, which contains the detailed financial outcomes for the period. Investors should refer to the press release (Exhibit 99) for specific figures regarding revenue, earnings, and other key financial metrics. While this 8-K itself does not provide the granular financial data, it formally announces the availability of Pfizer's Q3 2023 financial results. The furnishing of this information under Item 2.02 signifies that the company is disclosing material information to the public. Investors seeking a comprehensive understanding of Pfizer's performance in the third quarter will need to consult the referenced press release.
Key Highlights
- 1Pfizer Inc. (PFE) reported its third quarter 2023 financial results on October 31, 2023.
- 2The 8-K filing incorporates by reference a press release containing the Q3 2023 financial results.
- 3Investors should consult the furnished press release (Exhibit 99) for detailed financial performance data.
- 4The filing does not contain specific financial figures within the 8-K document itself.
- 5This report is primarily a procedural notification of the earnings release.
- 6The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act, unless specifically incorporated by reference into other filings.